51KB Stock Overview Operates as a regenerative medicine company in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
AVITA Medical, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for AVITA Medical Historical stock prices Current Share Price US$1.90 52 Week High US$3.30 52 Week Low US$1.44 Beta 1.55 1 Month Change 14.46% 3 Month Change -13.64% 1 Year Change -39.87% 3 Year Change 15.85% 5 Year Change -80.04% Change since IPO -95.48%
Recent News & Updates
Avita Medical, Inc. Provides Revenue Guidance for 2025 Feb 15 AVITA Medical, Inc. has filed a Follow-on Equity Offering. Feb 14
AVITA Medical, Inc. Updates Revenue Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024
AVITA Medical, Inc. Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds Dec 24
AVITA Medical, Inc. Announces FDA510(K) Clearance for Cohealyx, Expanding Its Addressable Market Dec 20
AVITA Medical, Inc. Provides Financial Guidance for Fourth Quarter and Full Year of 2024 Nov 09 See more updates
Avita Medical, Inc. Provides Revenue Guidance for 2025 Feb 15 AVITA Medical, Inc. has filed a Follow-on Equity Offering. Feb 14
AVITA Medical, Inc. Updates Revenue Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024
AVITA Medical, Inc. Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds Dec 24
AVITA Medical, Inc. Announces FDA510(K) Clearance for Cohealyx, Expanding Its Addressable Market Dec 20
AVITA Medical, Inc. Provides Financial Guidance for Fourth Quarter and Full Year of 2024 Nov 09
AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
AVITA Medical, Inc. Provides Financial Guidance for Third Quarter 2024 and Updates Financial Guidance for Full Year 2024 Aug 09
AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales Aug 02
AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12
AVITA Medical, Inc. Announces Executive Changes Jul 02
AVITA Medical, Inc. Announces FDA Approval of RECELL GO May 31
AVITA Medical, Inc. Provides Earnings Guidance for the Second of 2024 May 15
AVITA Medical, Inc., Annual General Meeting, Jun 05, 2024 Apr 24 AVITA Medical, Inc. to Report Q3, 2024 Results on May 13, 2024
AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 Feb 24
AVITA Medical, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 02
Avita Medical, Inc. Provides Preliminary Revenue Guidance for Fourth Quarter and Full-Year 2023 and First Quarter and Year 2024 Jan 10
AVITA Medical, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 20 AVITA Medical, Inc. announced that it expects to receive $90 million in funding from OrbiMed Advisors LLC
New minor risk - Shareholder dilution Aug 29
AVITA Medical, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023 Aug 11
Second quarter 2023 earnings released: US$0.082 loss per share (vs US$0.05 loss in 2Q 2022) Aug 11
AVITA Medical, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 23 AVITA Medical, Inc. Submits FDA PMA Supplement for Recell Go Jun 30
AVITA Medical, Inc. Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients Jun 17
AVITA Medical, Inc. Announces Appointment of David O’Toole as Chief Financial Officer Jun 16
AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects Jun 08
First quarter 2023 earnings released: US$0.073 loss per share (vs US$0.076 loss in 1Q 2022) May 14
AVITA Medical, Inc. Expects FDA Submission of Recell Go by June 30, 2023 May 13
Now 31% undervalued May 12
AVITA Medical, Inc. Announces Executive Changes May 12
Full year 2022 earnings released: US$0.21 loss per share (vs US$0.23 loss in FY 2021) Feb 26 AVITA Medical, Inc. to Report Q4, 2022 Results on Feb 23, 2023
AVITA Medical, Inc. Submits FDA PMA Application for Vitiligo Dec 20
AVITA Medical, Inc. Submits PMA Supplement for Soft Tissue Repair Dec 13
Third quarter 2022 earnings released: US$0.045 loss per share (vs US$0.048 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: US$0.045 loss per share (vs US$0.048 loss in 3Q 2021) Nov 12
AVITA Medical, Inc. Revises Financial Guidance for the Year 2022 Nov 11
AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL System for Soft Tissue Repair Nov 10
AVITA Medical, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 21
AVITA Medical, Inc., Annual General Meeting, Dec 12, 2022 Oct 20
AVITA Medical, Inc. Announces Executive Changes Sep 30
AVITA Medical, Inc. Announces Chief Executive Officer Changes Sep 29
AVITA Medical, Inc. Announces Positive Topline Results from A Pivotal Randomized, Controlled Trial Evaluating the Safety and Effectiveness of the RECELL® System for Repigmentation of Stable Vitiligo Lesions Sep 13
RECELL Insurance Coverage Begins in Japan for Acute Burns Sep 02
Second quarter 2022 earnings released: US$0.05 loss per share (vs US$0.038 loss in 2Q 2021) Aug 13 AVITA Medical, Inc. Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries Using the Recell System
AVITA Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 26 AVITA Medical, Inc.(NasdaqCM:RCEL) dropped from Russell 2000 Growth Index
Avita Medical, Inc. Provides Guidance for Year 2022 May 13
Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors Apr 22
Forecast to breakeven in 2024 Mar 03
Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations Mar 02
AVITA Medical, Inc. Provides Revenue Guidance for the Calendar Year 2022 Mar 01
AVITA (AVH) Announces RECELL Receives Japan PMDA Approval Feb 24
AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use Feb 18
AVITA Medical, Inc. to Report First Half, 2022 Results on Feb 28, 2022 Feb 16
Forecast to breakeven in 2024 Jan 21 AVITA Medical, Inc. Establishes Proof of Concept for Gene Therapy
AVITA Medical, Inc. Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo Dec 16
First quarter 2022 earnings released: US$0.048 loss per share (vs US$0.095 loss in 1Q 2021) Nov 09
AVITA Medical, Inc. Provides Revenue Guidance for the First Quarter of Fiscal Year 2022 Aug 27
Full year 2021 earnings released: US$0.23 loss per share (vs US$0.41 loss in FY 2020) Aug 27
FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical, Inc.'s Pivotal Study of the RECELL® System for Vitiligo Treatment Aug 17
AVITA Medical, Inc. Provides Revenue Guidance for the Fourth Quarter Ending June 30, 2021 Jun 18
Avita Medical, Inc. Announces Preliminary Unaudited Financial Results for the Fiscal Fourth Quarter Ending June 30, 2021 Jun 16
U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients Jun 11
Forecast to breakeven in 2024 May 20
Third quarter 2021 earnings released: US$0.053 loss per share (vs US$0.14 loss in 3Q 2020) May 15
AVITA Medical, Inc. Provides Earnings Guidance for 2021 May 14
AVITA Medical, Inc. Will Not Provide Financial Guidance At This Time Feb 12 AVITA Medical, Inc. to Report Q2, 2021 Results on Feb 11, 2021
New 90-day high: €4.28 Jan 20
New 90-day low: €3.37 Dec 08
AVITA Therapeutics, Inc. Appoints Kathy McGee as Chief Operating Officer, Effective December 1, 2020 Dec 01
Revenue beats expectations Nov 11
First quarter 2021 earnings released: US$0.095 loss per share Nov 11
AVITA Therapeutics and the Houston Methodist Research Institute Enter into Collaboration to Explore Novel Approaches for Skin Rejuvenation Nov 09 AVITA Therapeutics, Inc. Announces Executive Changes
New 90-day low: €3.51 Oct 31
AVITA Therapeutics, Inc. to Report Q1, 2021 Results on Nov 11, 2020 Oct 28 Shareholder Returns 51KB DE Biotechs DE Market 7D 8.6% -3.2% 2.7% 1Y -39.9% -7.9% 17.0%
See full shareholder returns
Return vs Market: 51KB underperformed the German Market which returned 17% over the past year.
Price Volatility Is 51KB's price volatile compared to industry and market? 51KB volatility 51KB Average Weekly Movement 11.8% Biotechs Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 51KB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 51KB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2.
Show more AVITA Medical, Inc. Fundamentals Summary How do AVITA Medical's earnings and revenue compare to its market cap? 51KB fundamental statistics Market cap €266.26m Earnings (TTM ) -€58.94m Revenue (TTM ) €61.23m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 51KB income statement (TTM ) Revenue US$64.25m Cost of Revenue US$9.09m Gross Profit US$55.16m Other Expenses US$117.00m Earnings -US$61.84m
Last Reported Earnings
Dec 31, 2024
Earnings per share (EPS) -2.34 Gross Margin 85.85% Net Profit Margin -96.26% Debt/Equity Ratio 939.0%
How did 51KB perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/16 18:15 End of Day Share Price 2025/02/14 00:00 Earnings 2024/12/31 Annual Earnings 2024/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources AVITA Medical, Inc. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution John Hester Bell Potter Lyanne Harrison BofA Global Research Laura McGuigan B. Riley Securities, Inc.
Show 14 more analysts 
